newsfilter
← Latest News
ClinicalTrials.gov·

Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases - NCT04647916

Objective response rate (ORR), Overall survival, Progression-free survival, Incidence of adverse events